Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.
Lancet Oncol, May 2020
Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study.
Lancet Oncol, March 2020
Atezolizumab and bevacizumab : a new first line treatment of advanced hepatoellular carcinoma
New England Journal of Medicine, May 2020
Growth patterns of hepatocellular carcinoma
NCBI, February 2020
Cooperation Between MYC and β-Catenin in Liver Tumorigenesis Requires Yap/
Hepatology, January 2020